Formulations

Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More


  • No Image
    Ra Chem Pharma Ltd

    RA Chem Pharma Ltd incorporated in January 1996, has been promoted by Mr J Rajender Rao, Mr R Sirish Kumar, Mr Ravi K Yerra, Dr B Srinivas Reddy and Mr Harcharan Singh. RACPL is

  • No Image
    Rajasthan Antibiotics Ltd

    Rajasthan Antibiotics Ltd. (RAL) commenced commercial production in 1991 and has grown in size and stature to become the country's largest producer of the injectable antibiotics